Many fair-skinned people (including redheads) suffer from rosacea, a chronic, inflammatory skin condition that affects an estimated 16MM Americans, and one of the most common (and often frustrating!) symptoms is persistent facial redness. Most girls turn to makeup to cover it up because they don’t know persistent facial redness is now treatable.

Hold it, right there! Rosacea. is. treatable?!

We’ll get to that in just one minute. First, let’s go down memory lane a little bit. Do you remember when makeup use to be fun? Experimenting with bright colors, sparkles and gloss made you feel beautiful and mysterious. Now, makeup is boring and skin-toned to cover-up redness; thick foundation, concealer and power are a necessity to feel comfortable in your skin.

All redheads should feel confident, look amazing and rock their beauty. There is no need to feel self-conscious about rosacea if you can treat the persistent facial redness with Mirvaso® (brimonidine) topical gel, 0.33%*. It’s time to stop being captive to your concealer, to lose the layers of foundation and to skip the powder, because now you can directly treat the facial redness of rosacea rather than struggle to hide it. Stop concealing and start treating the facial redness of rosacea.

To celebrate breaking up with your makeup and having “red carpet ready” skin, Mirvaso is hosting a campaign called, “Break Up with Your Makeup.”

SIMPLY ENTER BELOW AND YOU COULD WIN A TRIP TO THE EMMY’S! 

Have fun entering, enjoy your clear skin and Rock it like a Redhead!

Important Safety Information Indication: Mirvaso® (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years of age or older. Adverse Events: In clinical trials, the most common adverse reactions (≥1%) included erythema, flushing, skin burning sensation and contact dermatitis. Warnings/Precautions: Mirvaso Gel should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud’s phenomenon, orthostatic hypotension, thromboangiitis obliterans, scleroderma, or Sjögren’s syndrome. Alpha-2 adrenergic agents can lower blood pressure. Mirvaso Gel should be used with caution in patients with severe or unstable or uncontrolled cardiovascular disease. Serious adverse reactions following accidental ingestion of Mirvaso Gel by children have been reported. Keep Mirvaso Gel out of reach of children. Not for oral, ophthalmic, or intravaginal use. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. *Each gram of gel contains 5 mg of brimonidine tartrate, equivalent to 3.3 mg of brimonidine free base.